LydiaRx
Programmes in motion

Your genome. Your asset. Your terms.

Every programme follows the same model. A privately financed pilot of a few hundred long-read genomes. A national pangenome built in-country. A laboratory and secure environment that stay. A trained team. A published governance standard. And a research-access framework that pays for what comes next. From the first participant, it is designed to become the national programme.

Six countries

Pakistan

A 400-genome long-read pilot and the first Pakistani pangenome, sequenced entirely in Pakistan. 12–15 Pakistani scientists trained and certified. A laboratory and secure data environment that remain a national asset. All designed to lead into a one-million-genome national programme. Read more →

Proposal submitted under the Public Procurement Rules · technical team mobilised

Maldives

A sovereign cohort and the first Maldivian pangenome, sized to an island nation, with the governed-access model that makes a small cohort valuable to research partners.

In discussion

Albania

A national cohort, pangenome and in-country capability on the same model, scaled to the country and its diaspora science base.

Proposal presented

Türkiye

A 500 + 500 programme: a national long-read cohort and pangenome alongside a pathogen-genomics and surveillance pillar.

Proposal presented

Saudi Arabia

A sovereign genomics programme delivered through an in-Kingdom venture: platform, laboratory operations, scientific delivery and data governance run by LydiaRx with Saudi partners.

Design complete

South Africa

A long-read pangenome pillar and a governed-access layer proposed alongside the national genome programme, where neither yet exists.

Assessed · pillar proposal prepared
A clear division of ownership

What we supply. What you keep.

What LydiaRx supplies

  • The sovereign platform: custody, consent enforcement, metering and provenance.
  • Programme design: phasing, supply chain, laboratory-network model and the reference method.
  • Legal architecture: concession or partnership structure, joint-venture design, supplier terms, and the data-sovereignty and licence framework.
  • Governance design: independent oversight, data-access rules, ethics pathway and published audit.
  • The operator of the secure environment and the research gateway. We work under the same controls as every partner.

What the country keeps

  • Every sample and every genome.
  • Ownership of the national pangenome and every dataset derived from it.
  • Access control: a national-majority Data Access Committee decides every use.
  • A defined share of research-access fees and royalties, under audited terms.
  • The capability: the laboratory, the environment, the team and a tested governance standard.
What stays

Four things that stay when we have gone.

A pilot is judged by what remains after the final report. We design every programme backwards from that. None of it depends on LydiaRx staying.

Infrastructure A national genomecentre in a publicinstitution: laboratory,biobank, in-countrycompute-to-dataenvironment, genomeportal. Everythinginstalled stays in thecountry. People Twelve to fifteennational scientists andstaff recruited andemployed at home,trained and certified onthe full workflow. A cadrethat stays whether or notany partner does. Health system A national pangenomeand variant catalogue;the evidence base forcarrier, prenatal andnewborn screening;pharmacogenomicguidance royalty-free inthe public system. Economy andscience A governed researchresource that partnerspay to work on insidethe country; nationalscientists as seniorauthors; a governancestandard theGovernment can adoptas policy. Four things that stay when we have gone
12months from ethics approval to a published pangenome, a certified team and a costed design for the next stage
12–15national scientists and staff trained, certified and employed at home
0samples or genomes leaving the country, and no public money needed to start
How we engage

Three steps, each verifiable before the next.

Each step is sized so that a government commits nothing it cannot verify before the next step is taken.

Step 1

Feasibility mandate

A non-obligatory blueprint: track selection, entity design, the regulatory map, the funding model and the sponsor-engagement plan. The government receives a document it can test. It commits to nothing.

Step 2

Concept note and MoU

An in-country programme lead and local counsel appointed; the in-country operating company designed; academic and clinical partners identified; a demonstration pilot scoped and costed.

Step 3

Definitive partnership

The concession or partnership agreement, the supplier terms and the data-sovereignty and licence framework are executed. The demonstration pilot is delivered and independently audited before any decision to scale.

Ready to build your country's genome programme?

Start with a feasibility mandate. It is a document you can test, and it commits you to nothing.